Biosensors International

Biosensors International is a medical-device company associated with the development, manufacture, and licensing of technologies used in interventional cardiology and critical-care procedures. Its principal identity is built around coronary stent systems and related platform technologies, with the company also licensing proprietary drug-eluting stent technology to other medical-device businesses and specialist stent providers. The company’s global headquarters, manufacturing operations, and research and development activities are based in Singapore. It has also maintained a European headquarters in Morges, Switzerland. The Swiss operation is identified as the legal manufacturer of BioMatrix, the company’s leading product in the supplied reference material. This structure reflects Biosensors International’s international operating model: product development and corporate activity centered in Singapore, regulatory and manufacturing responsibilities distributed across international facilities, and commercial relationships extending through licensing and joint ventures. Biosensors’ best-known product platform is BioMatrix, a drug-eluting coronary stent. The system combines an S-Stent platform with a biodegradable poly-lactic acid polymer, the drug Biolimus A9, and an automated coating process that deposits the coating directly onto the stent surface. The polymer is designed to degrade into naturally occurring lactic acid, while Biolimus A9 is described as a highly lipophilic derivative of sirolimus. Biosensors obtained approval for BioMatrix in January 2008. In addition to selling products under its own platform, the company has licensed proprietary drug-eluting stent technologies to medical-device and specialty-stent companies including Terumo, Devax, Inc., and Xtent, Inc. It has also participated in a Hong Kong-listed joint venture with Shandong Weigao to market and distribute coronary stents in China. These arrangements indicate that Biosensors International has pursued a combination of direct product development, technology licensing, and regional commercialization partnerships rather than relying exclusively on a single sales channel. The company became a publicly traded business when Biosensors International Group was listed on the mainboard of the Singapore Exchange in May 2005. The supplied material does not establish its current listing status, ownership, financial performance, executive leadership, or operational status. Accordingly, those aspects remain unresolved in this dossier.

Biosensors International Group, Ltd. developed as a medical-device company specializing in technologies for interventional cardiology and critical care. Its activities have included product development, manufacturing, and the licensing of proprietary technologies to other companies in the medical-device sector. The supplied reference material does not identify the company’s founding year or founder. The company’s corporate and industrial base was established in Singapore, where its global headquarters, principal manufacturing facilities, and research and development centers were located. Biosensors also operated a European headquarters in Morges, Switzerland. The Swiss office served as the legal manufacturer of BioMatrix, a drug-eluting coronary stent that became the company’s leading identified product. A major corporate milestone occurred in May 2005, when Biosensors International Group was listed on the mainboard of the Singapore Exchange. The listing marked the company’s expansion as an international medical-technology business and provided a public-market platform for its development and commercialization activities. No ticker symbol or subsequent delisting information is provided in the available material. Biosensors’ technology strategy extended beyond products sold under its own name. The company licensed proprietary drug-eluting stent technologies to other medical-device companies and specialist stent providers, including Terumo, Devax, Inc., and Xtent, Inc. Licensing allowed the company’s technology to reach additional commercial and clinical channels while complementing its own product portfolio. The company also developed a presence in China through a Hong Kong-listed joint venture with Shandong Weigao. That venture was established to market and distribute coronary stents in the Chinese market, giving Biosensors a partnership-based route into a major regional healthcare market. BioMatrix represented an important product-development milestone. The drug-eluting stent incorporated four highlighted elements: an S-Stent structural platform; Biolimus A9, a highly lipophilic derivative of sirolimus; a biodegradable poly-lactic acid polymer; and an automated coating process that directly applied the coating to the stent surface. The biodegradable polymer was designed to break down into naturally occurring lactic acid. Biosensors obtained approval for the product in January 2008. The available sources do not provide a reliable account of later product generations, acquisitions, changes in ownership, executive succession, financial results, or the company’s present operating status. The historical record in this dossier therefore ends with the documented BioMatrix approval and the company’s known licensing and distribution structure.

• 2008

  BioMatrix approval

  [1]Biosensors Internationalen.wikipedia.org

  Biosensors obtained approval for BioMatrix, a drug-eluting coronary stent using Biolimus A9, a biodegradable poly-lactic acid polymer, the S-Stent platform, and automated coating technology.

• 2005

  Mainboard listing on the Singapore Exchange

  [1]Biosensors Internationalen.wikipedia.org

  Biosensors International Group was listed on the mainboard of the Singapore Exchange in May 2005.

A specialist medical-device and technology company serving interventional cardiology through coronary stents, drug-elivery platforms, proprietary coating systems, licensing, and regional distribution partnerships.

• Drug-eluting coronary stent · 2008

  BioMatrix

  BioMatrix is a drug-eluting coronary stent identified as Biosensors International’s leading product in the supplied reference material. Its design combines the S-Stent platform with Biolimus A9, a highly lipophilic derivative of sirolimus, and a biodegradable poly-lactic acid polymer intended to degrade into naturally occurring lactic acid. The product also uses an automated process that deposits the coating directly onto the stent surface. Biosensors obtained approval for BioMatrix in January 2008, and the Swiss operation was identified as its legal manufacturer.

• Coronary stent platform

  S-Stent

  S-Stent is the underlying stent platform incorporated into BioMatrix. The supplied source identifies it as one of the proprietary technology components used in Biosensors International’s drug-eluting stent system. Detailed specifications, later generations, and current commercial availability are not established by the available material.

• Drug-delivery and stent technology

  Biolimus A9 drug-eluting stent technology

  Biosensors International’s drug-eluting stent technology uses Biolimus A9, described in the reference material as a highly lipophilic derivative of sirolimus. The technology formed part of the BioMatrix system and was also associated with the company’s licensing activities involving other medical-device companies and specialty stent providers.

• 2008

  BioMatrix regulatory approvalProduct launch

  Background

  Biosensors was advancing a drug-eluting coronary stent based on its S-Stent platform, Biolimus A9, biodegradable polymer, and direct automated coating process.

  Action taken

  The company obtained approval for BioMatrix in January 2008.

  Aftermath

  BioMatrix became the leading product identified for Biosensors International, with the Swiss operation serving as its legal manufacturer.

  Source

• 2005

  Public-market expansion through Singapore listingStrategy

  Background

  Biosensors International Group was developing an international medical-device business based on interventional cardiology technologies and entered the public markets.

  Action taken

  The company listed on the mainboard of the Singapore Exchange in May 2005.

  Aftermath

  The listing established Biosensors as a publicly traded Singapore-based medical-device group. The available sources do not document subsequent financial or ownership consequences.

  Source

1. 1Biosensors Internationalen.wikipedia.org